The efficacy of aprepitant for the prevention of postoperative nausea and vomiting after bariatric surgery.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-508849-40-00

Acronym

PONVApr1

Enrollment

260

Registered

2024-04-02

Start date

2024-04-11

Completion date

Unknown

Last updated

2025-01-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative nausea and vomiting

Brief summary

Incidence of PONV, Severity of PONV measured by NRS (numeric rate scale) and Rhodes scale, Use of rescue medication, type and dose.

Detailed description

Correlation between intraabdominal pressure during surgery and PONV incidence and severity., Length of stay in recovery room, Length of hospital stay, Subjective patient satisfaction assessment NRS (1-10) of postoperative period.

Interventions

DRUGAprepitant Sandoz

DRUG125 mg

DRUGkõvakapslid + Aprepitant Sandoz

DRUG80 mg

DRUGkõvakapslid

DRUGPlatseebo 80mg kõvakapsel Läbipaistmatu

DRUGželatiinist kõvakapsel suurusega 2

DRUGvalge kapslikeha ja valge kapslikaanega

DRUGsisaldab glükoosi Placebo will be produced by East Tallinn-Central Hospital Pharmacy.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Secondary

Measure	Time frame
Correlation between intraabdominal pressure during surgery and PONV incidence and severity., Length of stay in recovery room, Length of hospital stay, Subjective patient satisfaction assessment NRS (1-10) of postoperative period.	—

Primary

Measure	Time frame
Incidence of PONV, Severity of PONV measured by NRS (numeric rate scale) and Rhodes scale, Use of rescue medication, type and dose.	—

Countries

Estonia

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026